CARLSBAD, Calif., Dec. 17,
2019 /PRNewswire/ -- Prescient Metabiomics, a subsidiary of
Prescient Medicine Holdings, Inc., and CoreBiome, a wholly owned
subsidiary of OraSure Technologies, Inc., announced today a
collaboration to develop a new test called LifeKit® Prevent,
which may represent a microbiome-driven paradigm shift in colon
cancer screening.
According to the American Cancer Society, colorectal cancer is
the third leading cause of cancer-related deaths in men and in
women, and the second most common cause of cancer deaths when men
and women are combined. Yet, there is a lack of non-invasive
screening tests that can accurately detect precancerous polyps as
effectively as a colonoscopy. The current standard of
care for colon cancer prevention is in-clinic screening via
colonoscopy, but approximately 1 in 3 patients are not up-to-date
with their necessary colon cancer screenings. Research
indicates that early detection of precancerous adenomas and
carcinomas could lead to significantly better patient
outcomes.
To help address this issue, Prescient Metabiomics is developing
a unique assay for predicting precancerous adenomas and carcinomas
that uses microbial biomarkers as a diagnostic platform.
Prescient Metabiomics has teamed up with CoreBiome to utilize
shotgun metagenomics DNA sequencing, machine learning and AI-driven
microbiome analytics to accelerate their development pipeline.
About the Colon Cancer Microbiome Diagnostics
Collaboration
"CoreBiome's DNA sequencing platform and
innovative bioinformatics methods for data analysis will be
critical for development of the LifeKit® Prevent test," said
Prescient Medicine CEO Dr. Keri
Donaldson. "Prescient Metabiomics will leverage CoreBiome's
discovery platform to accelerate development and validation through
the FDA's Breakthrough Devices Program."
"CoreBiome is committed to producing ultra-high-quality data at
very large scales and helping customers perform data mining for
clinical biomarkers. We are excited to help Prescient Metabiomics
move into the clinic faster by combining our precisely controlled
data generation with Prescient Metabiomics' customized analysis
algorithms and machine learning," said CoreBiome CEO Dan Knights.
About Prescient Metabiomics
Prescient Metabiomics
LLC, a privately held molecular diagnostics company and subsidiary
of Prescient Medicine Holdings, Inc, is an early stage molecular
diagnostics company that is developing in-vitro diagnostics that
leverage breakthroughs in next-generation DNA sequencing,
computational systems biology, and human microbiome sciences.
Prescient Metabiomics is a subsidiary of Prescient Medicine
Holdings, Inc. To learn more, visit www.prescientmedicine.com.
About CoreBiome
CoreBiome is a microbiome genomics
company focused on accelerating microbiome discovery for customers
in the pharmaceutical, agriculture, and research communities to
unleash the translational potential of the microbiome. The
company's proprietary BenchMark™, BoosterShot™, and Core Analysis™
platforms provide fast and information-rich characterizations of
microbial diversity and function, paired with machine learning and
expert analytics. CoreBiome is a wholly-owned subsidiary of OraSure
Technologies, Inc. (NASDAQ: OSUR), which also owns DNA Genotek, a
leading provider of sampling and stabilization kits, bringing
together an end-to-end solution for robust microbiome discovery.
For more information about CoreBiome, visit
http://www.corebiome.com.
View original
content:http://www.prnewswire.com/news-releases/prescient-metabiomics-and-corebiome-collaborating-to-develop-breakthrough-colon-cancer-screening-test-300975475.html
SOURCE Prescient Medicine; CoreBiome